Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA MNEXSPIKE)) | MODERNA | UNK | — | IM |
skin rash in areas other than the injection site; This spontaneous case was reported by a consumer and describes the occurrence of RASH (skin rash in areas other than the injection site) in an 80-year-old female patient who received mRNA-1283 (MNEXSPIKE PFS) for COVID-19 prophylaxis. No Medical History information was reported. On 04-Sep-2025, the patient received dose of mRNA-1283 (MNEXSPIKE PFS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced RASH (skin rash in areas other than the injection site). At the time of the report, RASH (skin rash in areas other than the injection site) outcome was unknown. The action taken with mRNA-1283 (MNEXSPIKE PFS) (Intramuscular use) was unknown. Concomitant medications details were not reported by the reporter. Reporter wife received this injection on04-SEP-2025, and he received it on the same day. However, patient has developed a skin rash in areas other than the injection site and wanted to know if that was a normal side effect. Reporter had the same vaccine but did not experience any side effects. He doesn't want to share any other personal information and just wants to get the information regarding the side effects. Treatment details were not reported by the reporter.; Reporter's Comments: The benefit-risk relationship of the product is not affected by this report.